6-Nov-2025 7:30 AM CST - Business Wire Schrdinger to Present at Jefferies London Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with i
5-Nov-2025 3:05 PM CST - Business Wire Schrdinger Reports Third Quarter 2025 Financial Results Schrdinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrdinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industrys increasing demand for our leading computational platform, said Ramy Farid, Ph.D., chief executive officer of Schrdinger. While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the in
22-Oct-2025 7:30 AM CST - Business Wire Schrdinger to Announce Third Quarter 2025 Financial Results on November 5 Schrdinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational platform, whic
27-Aug-2025 7:30 AM CST - Business Wire Schrdinger to Present at Morgan Stanley Global Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery wi
25-Jul-2025 7:30 AM CST - Business Wire Schrdinger to Announce Second Quarter 2025 Financial Results on August 6 Schrdinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational platform, which
22-May-2025 7:30 AM CST - Business Wire Schrdinger to Present at Jefferies Global Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational
14-May-2025 8:30 AM CST - Business Wire Schrdinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma Schrdinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet
5-May-2025 7:30 AM CST - Business Wire Schrdinger to Present at BofA Securities 2025 Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computatio
13-Jan-2025 6:00 AM CST - Business Wire Schrdinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities Schrdinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical
6-Nov-2025 7:30 AM CST - Business Wire Schrdinger to Present at Jefferies London Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with i
5-Nov-2025 3:05 PM CST - Business Wire Schrdinger Reports Third Quarter 2025 Financial Results Schrdinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrdinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industrys increasing demand for our leading computational platform, said Ramy Farid, Ph.D., chief executive officer of Schrdinger. While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the in
22-Oct-2025 7:30 AM CST - Business Wire Schrdinger to Announce Third Quarter 2025 Financial Results on November 5 Schrdinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational platform, whic
27-Aug-2025 7:30 AM CST - Business Wire Schrdinger to Present at Morgan Stanley Global Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery wi
25-Jul-2025 7:30 AM CST - Business Wire Schrdinger to Announce Second Quarter 2025 Financial Results on August 6 Schrdinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational platform, which
22-May-2025 7:30 AM CST - Business Wire Schrdinger to Present at Jefferies Global Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computational
14-May-2025 8:30 AM CST - Business Wire Schrdinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma Schrdinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet
5-May-2025 7:30 AM CST - Business Wire Schrdinger to Present at BofA Securities 2025 Healthcare Conference Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the Investors section of Schrdingers website and will be archived for approximately 90 days following the event. About Schrdinger Schrdinger is transforming molecular discovery with its computatio
13-Jan-2025 6:00 AM CST - Business Wire Schrdinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities Schrdinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical
